Hinge Health, Inc. Class A (HNGE) Stock Forecast & Price Target

Compare

109 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HNGE Analyst Ratings

Strong Buy

14 Buy

0 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Hinge

Health, Inc. Class A

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HNGE Stock 12 Month Forecast

Average Price Target

$48.08

▼(-0.29% Downside)

Based on 14 Wall Street analysts offering 12 month price targets for Hinge Health, Inc. Class A in the last 3 months. The average price target is $48.08 with a high forecast of $58.00 and a low forecast of $41.00. The average price target represents a -0.29% change from the last price of $48.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","44":"$44","49":"$49","54":"$54","59":"$59"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,44,49,54,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.95,45.95384615384616,46.95769230769231,47.96153846153847,48.965384615384615,49.96923076923077,50.973076923076924,51.97692307692308,52.98076923076923,53.98461538461538,54.988461538461536,55.99230769230769,56.996153846153845,{"y":58,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.95,45.190769230769234,45.431538461538466,45.6723076923077,45.91307692307692,46.15384615384615,46.394615384615385,46.635384615384616,46.87615384615385,47.11692307692308,47.357692307692304,47.598461538461535,47.83923076923077,{"y":48.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.95,44.64615384615385,44.34230769230769,44.03846153846154,43.73461538461539,43.43076923076923,43.12692307692308,42.823076923076925,42.519230769230774,42.215384615384615,41.91153846153846,41.60769230769231,41.30384615384615,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.16,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.45,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$58.00

Average Price Target$48.08

Lowest Price Target$41.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$52

Hold

7.84%

Upside

08/05/25

Hinge Health, Inc. is showing strong financial performance with robust revenue growth and effective cost management. Technical indicators suggest positive short-term momentum, and the valuation appears reasonable. However, ongoing profitability challenges and the lack of dividend yield are concerns.

Saket KaliaBarclays

Barclays

$51

Buy

5.77%

Upside

Reiterated

08/04/25

Barclays Sticks to Their Buy Rating for Hinge Health, Inc. Class A (HNGE)

David GrossmanStifel Nicolaus

Stifel Nicolaus

$48→$55

Buy

14.06%

Upside

Reiterated

08/01/25

Stifel Nicolaus Keeps Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Jailendra SinghTruist Financial

Truist Financial

―

Buy

―

Reiterated

07/28/25

Truist Financial Sticks to Their Buy Rating for Hinge Health, Inc. Class A (HNGE)

Richard CloseCanaccord Genuity

Canaccord Genuity

$52

Buy

7.84%

Upside

Reiterated

07/27/25

Hinge Health, Inc.: Promising Growth and Strong Financial Performance Justify Buy Rating

Rishi JaluriaRBC Capital

RBC Capital

$45

Buy

-6.68%

Downside

Reiterated

07/20/25

Hinge Health, Inc. Class A (HNGE) Gets a Buy from RBC Capital

Aaron KimsonCitizens JMP

Citizens JMP

$58

Buy

20.28%

Upside

Initiated

07/14/25

Hinge Health initiated with an Outperform at Citizens JMPHinge Health initiated with an Outperform at Citizens JMP

Brian PetersonRaymond James

Raymond James

$45

Buy

-6.68%

Downside

Initiated

06/16/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Sarepta Therapeutics (NASDAQ: SRPT) and Privia Health Group (NASDAQ: PRVA)

Ryan MacDonaldNeedham

Needham

$47

Buy

-2.53%

Downside

Initiated

06/16/25

Analysts Offer Insights on Healthcare Companies: Elevation Oncology (NASDAQ: ELEV), Harrow Health (NASDAQ: HROW) and Hinge Health, Inc. Class A (NYSE: HNGE)

Bradley SillsBank of America Securities

Bank of America Securities

$42

Buy

-12.90%

Downside

Initiated

06/16/25

Hinge Health initiated with a Buy at BofAHinge Health initiated with a Buy at BofA

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Initiated

06/16/25

Hinge Health: A Compelling Buy with Innovative Digital Solutions and Favorable Valuation

Craig HettenbachMorgan Stanley

Morgan Stanley

$46

Buy

-4.60%

Downside

Initiated

06/16/25

Hinge Health initiated with an Overweight at Morgan StanleyHinge Health initiated with an Overweight at Morgan Stanley

Scott SchoenhausKeyBanc

KeyBanc

$45

Buy

-6.68%

Downside

Initiated

06/16/25

Hinge Health, Inc. Class A (HNGE) Gets a Buy from KeyBanc

Jessica TassanPiper Sandler

Piper Sandler

$41

Buy

-14.97%

Downside

Initiated

06/16/25

Hinge Health, Inc. Class A (HNGE) Receives a New Rating from Piper Sandler

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$50

Buy

3.69%

Upside

Initiated

06/16/25

Hinge Health initiated with an Outperform at Evercore ISIHinge Health initiated with an Outperform at Evercore ISI

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$52

Hold

7.84%

Upside

08/05/25

Saket KaliaBarclays

Barclays

$51

Buy

5.77%

Upside

Reiterated

08/04/25

Barclays Sticks to Their Buy Rating for Hinge Health, Inc. Class A (HNGE)

David GrossmanStifel Nicolaus

Stifel Nicolaus

$48→$55

Buy

14.06%

Upside

Reiterated

08/01/25

Stifel Nicolaus Keeps Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Jailendra SinghTruist Financial

Truist Financial

―

Buy

―

Reiterated

07/28/25

Truist Financial Sticks to Their Buy Rating for Hinge Health, Inc. Class A (HNGE)

Richard CloseCanaccord Genuity

Canaccord Genuity

$52

Buy

7.84%

Upside

Reiterated

07/27/25

Hinge Health, Inc.: Promising Growth and Strong Financial Performance Justify Buy Rating

Rishi JaluriaRBC Capital

RBC Capital

$45

Buy

-6.68%

Downside

Reiterated

07/20/25

Hinge Health, Inc. Class A (HNGE) Gets a Buy from RBC Capital

Aaron KimsonCitizens JMP

Citizens JMP

$58

Buy

20.28%

Upside

Initiated

07/14/25

Hinge Health initiated with an Outperform at Citizens JMPHinge Health initiated with an Outperform at Citizens JMP

Brian PetersonRaymond James

Raymond James

$45

Buy

-6.68%

Downside

Initiated

06/16/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Sarepta Therapeutics (NASDAQ: SRPT) and Privia Health Group (NASDAQ: PRVA)

Ryan MacDonaldNeedham

Needham

$47

Buy

-2.53%

Downside

Initiated

06/16/25

Analysts Offer Insights on Healthcare Companies: Elevation Oncology (NASDAQ: ELEV), Harrow Health (NASDAQ: HROW) and Hinge Health, Inc. Class A (NYSE: HNGE)

Bradley SillsBank of America Securities

Bank of America Securities

$42

Buy

-12.90%

Downside

Initiated

06/16/25

Hinge Health initiated with a Buy at BofAHinge Health initiated with a Buy at BofA

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Initiated

06/16/25

Hinge Health: A Compelling Buy with Innovative Digital Solutions and Favorable Valuation

Craig HettenbachMorgan Stanley

Morgan Stanley

$46

Buy

-4.60%

Downside

Initiated

06/16/25

Hinge Health initiated with an Overweight at Morgan StanleyHinge Health initiated with an Overweight at Morgan Stanley

Scott SchoenhausKeyBanc

KeyBanc

$45

Buy

-6.68%

Downside

Initiated

06/16/25

Hinge Health, Inc. Class A (HNGE) Gets a Buy from KeyBanc

Jessica TassanPiper Sandler

Piper Sandler

$41

Buy

-14.97%

Downside

Initiated

06/16/25

Hinge Health, Inc. Class A (HNGE) Receives a New Rating from Piper Sandler

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$50

Buy

3.69%

Upside

Initiated

06/16/25

Hinge Health initiated with an Outperform at Evercore ISIHinge Health initiated with an Outperform at Evercore ISI

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hinge Health, Inc. Class A

1 Month

xxx

Success Rate

2/2 ratings generated profit

Average Return

+18.40%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +18.40% per trade.

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+20.15%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +20.15% per trade.

1 Year

David GrossmanStifel Nicolaus

Success Rate

2/2 ratings generated profit

Average Return

+20.15%

reiterated a buy rating 6 days ago

Copying David Grossman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +20.15% per trade.

2 Years

xxx

Success Rate

2/2 ratings generated profit

Average Return

+20.15%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +20.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HNGE Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HNGE has received 21 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. HNGE average Analyst price target in the past 3 months is 48.08.

Each month's total comprises the sum of three months' worth of ratings.

HNGE Financial Forecast

HNGE Earnings Forecast

Next quarter’s earnings estimate for HNGE is $0.09 with a range of $0.06 to $0.11. The previous quarter’s EPS was $0.35. HNGE beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year HNGE has Outperformed its overall industry.

HNGE Sales Forecast

Next quarter’s sales forecast for HNGE is $125.38M with a range of $124.20M to $129.56M. The previous quarter’s sales results were $139.10M. HNGE beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year HNGE has Outperformed its overall industry.

HNGE Stock Forecast FAQ

What is HNGE’s average 12-month price target, according to analysts?

Based on analyst ratings, Hinge Health, Inc. Class A’s 12-month average price target is 48.08.

What is HNGE’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for HNGE, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HNGE a Buy, Sell or Hold?

Hinge Health, Inc. Class A has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.

What is Hinge Health, Inc. Class A’s price target?

The average price target for Hinge Health, Inc. Class A is 48.08. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $58.00 ,the lowest forecast is $41.00. The average price target represents -0.29% Decrease from the current price of $48.22.

What do analysts say about Hinge Health, Inc. Class A?

Hinge Health, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of HNGE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Hinge Health, Inc. Class A (HNGE) Stock Forecast & Price Target

HNGE Analyst Ratings

HNGE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hinge Health, Inc. Class A

HNGE Analyst Recommendation Trends

HNGE Financial Forecast

HNGE Earnings Forecast

HNGE Sales Forecast

HNGE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts